Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.” Email: jackfriday2011(at)hotmail.co.uk
Thursday, January 12, 2012
Thursday, June 30, 2011
Saturday, June 11, 2011
Wednesday, June 08, 2011
What word best describes J&J?
“Because of the diminished mental capacity of the patients being treated, this court finds the actions of the defendants, upon this (patient population), to be detestable,”
Tuesday, June 07, 2011
Friday, February 11, 2011
What were AstraZeneca's senior management telling Wall Street about Seroquel ten years ago?
Thursday, August 12, 2010
Wednesday, May 05, 2010
Monday, January 04, 2010
Monday, November 16, 2009
J&J - Risperdal: mis-selling mistrial mid-trial
Superior Court Judge Darlene Pereksta today threw out Lynn Powell’s lawsuit at the end of a three-week trial in Trenton, New Jersey. The jury hadn’t yet heard closing arguments or started deliberations. Powell, 36, claimed she was fired in 2004 for protesting so-called off-label sales.
Powell didn’t testify at the trial, which began Oct. 27. Pereksta ruled that Powell failed to prove she engaged in whistle-blowing as defined in New Jersey’s Conscientious Employee Protection Act. Her failure to take the witness stand prevented jurors from weighing her claims that she tried to disclose her concerns about off-label marketing, the judge said.
“Had she testified as to her intent, the jury could have assessed her credibility,” Pereksta said. “Without any testimony as to her intent, the jury is left to speculate.”
J&J, the world’s largest health-products company, said Powell was fired by its Janssen Pharmaceutica unit for violating company policy against off-label marketing, a widespread practice in the industry. Risperdal was the fourth-biggest seller for New Brunswick, New Jersey-based J&J in 2008, with sales of $3.4 billion.
The Powell lawsuit was the first Risperdal sales case to go before a jury.
Monday, November 02, 2009
Tuesday, May 06, 2008
What are we doing to our children?
And with scant long-term safety data, it's likely the drugs are being over-prescribed for both U.S. and U.K. children, research suggests.
Among the most commonly used drugs were those to treat autism and hyperactivity.
In the U.K. study, there were 595 anti-psychotic prescriptions for children in 1992, or a rate of fewer than four children per 10,000 using the drugs. By 2005, 2,917 prescriptions were written, or a rate of seven children per 10,000 — a near-doubling, said lead author Fariz Rani, a researcher at the University of London's School of Pharmacy.
The study is in the May edition of the journal Pediatrics.
More



